近年来，个体患者癌症基因组分析（CGP）已经变得更易于接触，允许使用癌症治疗中的驱动基因突变确定治疗策略。然而，这种针对特定患者的精准肿瘤学方法仍然处于实验阶段。在本研究中，我们验证了使用CGP指导恶性头颈肿瘤治疗的可行性和益处。我们目的是评估接受CGP的头颈恶性肿瘤患者的基因组分析和临床进展，以及CGP对头颈恶性肿瘤的治疗是否导致了有益的药物管理。我们分析了27名患者的CGP结果、预后和药物管理情况。这些患者已经完成（或预计完成）标准治疗，或者患有没有标准治疗的罕见癌症。在25（92.6%）名患者中，至少存在一种体细胞可操作的基因突变，每名患者可操作突变的中位数为4（范围为0-11）。有81.5%的患者有推荐临床试验用药的情况，但没有患者能够参加。然而，3名患者（11.1%）可以根据CGP结果使用已获批的药物进行离标使用。最常见的基因异常是TP53（66.7%），TP53突变导致预后不良。CGP在临床上有实际用途，并作为增加治疗选择的桥梁。然而，使用CGP确认的候选药物在给药时可能无效。因此，肿瘤学家不应盲目接受CGP的治疗建议，而应在适当验证后提供引导最佳治疗的建议。 版权所有 © 2023，国际抗癌研究所（乔治·J·德利纳西奥斯博士），保留所有权利。

In recent years, individual patient cancer genomic profiling (CGP) has become more accessible, allowing determination of therapeutic strategies using driver gene mutations in cancer therapy. However, this precision oncology approach, tailored to specific patients, remains experimental. In this study, we verified the feasibility and benefit of using CGP to guide treatment of malignant head and neck tumors. We aimed to evaluate the profiling and clinical courses of patients with head and neck malignancies who underwent CGP and determine the extent to which CGP for head and neck malignancies has resulted in beneficial drug administration.We analyzed CGP results, prognosis, and drug administration status in 27 patients. These patients had completed (or were expected to complete) standard therapy or had rare cancers without standard therapy.At least one somatic actionable gene alteration was seen in 25 (92.6%) patients, with a median number of actionable alterations per patient of 4 (range=0-11). Drugs in clinical trials were recommended to 22 (81.5%) patients, but none could participate. However, 3 patients (11.1%) could use approved drugs off-label based on CGP results. The most common genetic abnormality was TP53 (66.7%), with TP53 mutations leading to poor prognosis.CGP is clinically useful and serves as a bridge to increase the number of therapeutic options. However, candidate drugs confirmed using CGP may be ineffective when administered. Therefore, oncologists should not blindly accept CGP therapeutic recommendations but should make recommendations that lead to optimal therapies after proper verification.Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.